Clinical Trial Update: N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 dose-optimization trial of nicotinamide riboside for Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• Nicotinamide Riboside (nicotinamide riboside)

Snippet

Sponsor: Haukeland University Hospital | Conditions: Alzheimer Disease, Dementia | Phase 2 | Status: COMPLETED